Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ARO-DIMERPA

PreclinicalSmall molecule

Arrowhead Pharmaceuticals

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hyperlipidemia; MixedRecruiting

Hyperlipidemia; MixedPreclinical

Recruiting

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Hyperlipidemia; Mixed

NCT07223658

Clinical

Trials by Indication[1]

Hyperlipidemia; Mixed1 trial

Phase 1/2a, Double-blind, Placebo-controlled, Single and Multiple Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ARO-DIMERPA in Adult Subjects With Mixed Hyperlipidemia

Recruiting· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Preclinical·NCT07223658·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ARO-DIMERPA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARO-DIMERPA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARO-DIMERPA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arrowhead Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Arrowhead Pharmaceuticals

Related News